Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer

Tumor Biology ◽  
2014 ◽  
Vol 35 (7) ◽  
pp. 6847-6853 ◽  
Author(s):  
Ximing Wang ◽  
Yahong Fan ◽  
Jinliang Wang ◽  
Huaming Wang ◽  
Wenchao Liu
2016 ◽  
Vol 62 (09/2016) ◽  
Author(s):  
Ewa Wojcik ◽  
Jadwiga Tarapacz ◽  
Urszula Rychlik ◽  
Zofia Stasik ◽  
Beata Sas-Korczynska ◽  
...  

2020 ◽  
Vol 111 (5) ◽  
pp. 1699-1710
Author(s):  
Weidong Wang ◽  
Runzhou Zhuang ◽  
Honghai Ma ◽  
Likui Fang ◽  
Zhitian Wang ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Min Jiang ◽  
Xuelian Li ◽  
Xiaowei Quan ◽  
Xiaoying Li ◽  
Baosen Zhou

(1) Background. Non-small cell lung cancer (NSCLC) has a high mortality rate. MiRNAs have been found to be diagnostic biomarkers for NSCLC. However, controversial results exist. We conducted this meta-analysis to evaluate the diagnostic value of miRNAs for NSCLC.(2) Methods. Databases and reference lists were searched. Pooled sensitivity (SEN), specificity (SPE), and area under the curve (AUC) were applied to examine the general diagnostic efficacy, and subgroup analysis was also performed.(3) Results. Pooled SEN, SPE, and AUC were 85%, 88%, and 0.93, respectively, for 71 studies. Multiple miRNAs (AUC: 0.96) obtained higher diagnostic value than single miRNA (AUC: 0.86), and the same result was found for Caucasian population (AUC: 0.97) when compared with Asian (AUC: 0.91) and Caucasian/African population (AUC: 0.92). MiRNA had higher diagnostic efficacy when participants contained both smokers and nonsmokers (AUC is 0.95 for imbalanced group and 0.91 for balanced group) than when containing only smokers (AUC: 0.90). Meanwhile, AUC was 0.91 for both miR-21 and miR-210.(4) Conclusions. Multiple miRNAs such as miR-21 and miR-210 could be used as diagnostic tools for NSCLC, especially for the Caucasian and nonsmoking NSCLC.


2011 ◽  
Vol 104 (7) ◽  
pp. 836-840 ◽  
Author(s):  
Yu-Zhen Du ◽  
Xiao-Hua GU ◽  
Li Li ◽  
Feng Gao

2002 ◽  
Vol 17 (4) ◽  
pp. 275-279 ◽  
Author(s):  
M. Tamura ◽  
Y. Ohta ◽  
H. Nakamura ◽  
M. Oda ◽  
G. Watanabe

We assessed the diagnostic value of circulating VEGF as a tumor marker in patients with lung cancer and compared its clinical utility with that of other markers such as carcinoembryonic antigen (CEA) and cytokeratin 19 (CYFRA). One hundred and sixty non-small cell lung cancer patients and 70 healthy volunteers were included in the study. Circulating VEGF was assessed by enzyme-linked immunosorbent assay (ELISA). The serum concentrations of both CEA and CYFRA were measured by means of immunoradiometric assays. The diagnostic value of plasma VEGF (VEGFp) was better than that of CYFRA and similar to that of CEA. When the diagnostic value of VEGFp and CEA for the diagnosis of adenocarcinoma was compared, the two markers proved to have nearly equal discriminatory power. In diagnosing squamous cell carcinoma, VEGFp showed less discrimination than CYFRA. When the diagnostic value of VEGFp was analyzed for stage I adenocarcinoma patients, VEGFp was slightly more discriminatory than CEA. The combination assay of VEGFp and CEA had a sensitivity of 75% and a specificity of 60% at a cutoff of 104.4 pg/mL for VEGFp and 5.2 ng/mL for CEA. The combination of VEGF and CEA was superior to CEA alone in the early diagnosis of adenocarcinoma of the lung.


Sign in / Sign up

Export Citation Format

Share Document